Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABVD vs Stanford V in Advanced Hodgkin's Lymphoma
NCT00003389Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jun 1999
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of mechlorethamine, pegylated liposomal doxorubicin, vinblastine, vincristine sulfate liposome injection, bleomycin and 2 more in Hodgkin lymphoma (HL) (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Failure-free Survival at 5 years. Started Jun 1999; status: completed.
02
Drugs
mechlorethaminepegylated liposomal doxorubicinvinblastinevincristine sulfate liposome injectionbleomycin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00003389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003389.